Methods and devices for bone infection treatment selection
Inventors
Aronow, Bruce J. • Harley, John B. • Hostetter, Margaret • Kaufman, Kenneth
Assignees
Cincinnati Childrens Hospital Medical Center • US Department of Veterans Affairs
Publication Number
US-9999652-B2
Publication Date
2018-06-19
Expiration Date
2035-04-08
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed are methods for identifying patients at increased risk of developing disseminated staphylococcal infection, which includes the steps of determining that the patient has a mutation in one or more genes selected from a MPDZ network gene, a CGNL1 network gene, a PRKRIR network gene, a MED26 network gene, a tight junction protein gene, or an immune modulator gene; and treating the patient for disseminated staphylococcal infection. Also disclosed are solid substrates and/or assays useful for carrying out the disclosed methods.
Core Innovation
The invention provides methods for identifying patients at increased risk of developing disseminated staphylococcal infection by determining the presence of mutations in one or more genes selected from MPDZ network genes, CGNL1 network genes, PRKRIR network genes, MED26 network genes, tight junction protein genes, or immune modulator genes. Upon identifying such mutations, the patient is treated specifically for disseminated staphylococcal infection.
The problem addressed is that osteomyelitis, a common invasive childhood infection caused by Staphylococcus aureus, has poorly understood pathogenesis and host susceptibility is not well known. There is a need for compositions and methods to detect individuals susceptible to S. aureus so that appropriate treatment can be administered promptly.
Claims Coverage
The patent contains one independent claim focusing on a method of diagnosing and treating individuals at increased risk of disseminated staphylococcal infection. The inventive features include specific mutation detection and subsequent tailored treatment.
Detection of specific mutation in PRKRIR
The method involves obtaining a biological sample and detecting a Leu602Phe mutation in the PRKRIR gene using a labeled nucleic acid probe specific to and bound to this mutation.
Diagnosis of increased risk of disseminated staphylococcal infection
Diagnosing the individual as having an increased risk of disseminated staphylococcal infection upon detection of the Leu602Phe mutation in PRKRIR via the labeled nucleic acid probe.
Targeted treatment following diagnosis
Treating the identified individual with surgical intervention, a bactericidal antibiotic specific for Staphylococcus aureus, or a combination thereof after diagnosis.
The independent claim covers a diagnostic and treatment method directed to detecting a specific mutation in PRKRIR indicating risk for disseminated staphylococcal infection and applying appropriate treatment. Additional dependent claims extend detection to mutations in MPDZ, CGNL1, and MED26 genes.
Stated Advantages
Identification of patients at increased risk of disseminated staphylococcal infection for targeted and timely treatment.
Use of genetic biomarkers to stratify risk and guide effective therapeutic protocols including surgical intervention and bactericidal antibiotics.
Enables rapid risk stratification upon osteomyelitis diagnosis to improve treatment outcomes.
Documented Applications
Identifying subjects with osteomyelitis who are at genetic risk for disseminated staphylococcal infection to determine necessity for surgical intervention and/or treatment with bactericidal antibiotics.
Utilization of solid surface arrays or other assays for screening genetic mutations as a risk-stratification tool in bone infection treatment.
Interested in licensing this patent?